BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19356014)

  • 21. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
    Jada SR; Lim R; Wong CI; Shu X; Lee SC; Zhou Q; Goh BC; Chowbay B
    Cancer Sci; 2007 Sep; 98(9):1461-7. PubMed ID: 17627617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.
    Côté JF; Kirzin S; Kramar A; Mosnier JF; Diebold MD; Soubeyran I; Thirouard AS; Selves J; Laurent-Puig P; Ychou M
    Clin Cancer Res; 2007 Jun; 13(11):3269-75. PubMed ID: 17510208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
    Xu C; Tang X; Qu Y; Keyoumu S; Zhou N; Tang Y
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):119-30. PubMed ID: 27220761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
    Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
    Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
    Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.
    Michael M; Thompson M; Hicks RJ; Mitchell PL; Ellis A; Milner AD; Di Iulio J; Scott AM; Gurtler V; Hoskins JM; Clarke SJ; Tebbut NC; Foo K; Jefford M; Zalcberg JR
    J Clin Oncol; 2006 Sep; 24(26):4228-35. PubMed ID: 16896007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
    Toffoli G; Cecchin E; Corona G; Russo A; Buonadonna A; D'Andrea M; Pasetto LM; Pessa S; Errante D; De Pangher V; Giusto M; Medici M; Gaion F; Sandri P; Galligioni E; Bonura S; Boccalon M; Biason P; Frustaci S
    J Clin Oncol; 2006 Jul; 24(19):3061-8. PubMed ID: 16809730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
    Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
    Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
    Fakih MG; Ross ME; Starostik P
    Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.
    Di Paolo A; Bocci G; Polillo M; Del Re M; Di Desidero T; Lastella M; Danesi R
    Curr Drug Metab; 2011 Dec; 12(10):932-43. PubMed ID: 21787264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes.
    Tsunedomi R; Hazama S; Fujita Y; Okayama N; Kanekiyo S; Inoue Y; Yoshino S; Yamasaki T; Suehiro Y; Oba K; Mishima H; Sakamoto J; Hamamoto Y; Oka M
    Int J Oncol; 2014 Oct; 45(4):1381-90. PubMed ID: 25175642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer.
    Fukuda M; Okumura M; Iwakiri T; Arimori K; Honda T; Kobayashi K; Senju H; Takemoto S; Ikeda T; Yamaguchi H; Nakatomi K; Matsuo N; Mukae H; Ashizawa K
    Thorac Cancer; 2018 Jan; 9(1):51-58. PubMed ID: 29052349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients.
    Li J; Yu Q; Fu S; Xu M; Zhang T; Xie C; Feng J; Chen J; Zang A; Cai Y; Fu Q; Liu S; Zhang M; Hong Q; Huang L; Yuan X
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1621-8. PubMed ID: 27160286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
    De Mattia E; Toffoli G; Polesel J; D'Andrea M; Corona G; Zagonel V; Buonadonna A; Dreussi E; Cecchin E
    Pharmacogenet Genomics; 2013 Oct; 23(10):549-57. PubMed ID: 24018773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insights, challenges, and future directions in irinogenetics.
    Kim TW; Innocenti F
    Ther Drug Monit; 2007 Jun; 29(3):265-70. PubMed ID: 17529881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.
    Shulman K; Cohen I; Barnett-Griness O; Kuten A; Gruber SB; Lejbkowicz F; Rennert G
    Cancer; 2011 Jul; 117(14):3156-62. PubMed ID: 21287524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
    Biason P; Masier S; Toffoli G
    J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics of irinotecan disposition and toxicity: a review.
    Fujita K; Sparreboom A
    Curr Clin Pharmacol; 2010 Aug; 5(3):209-17. PubMed ID: 20406168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irinogenetics: how many stars are there in the sky?
    Mathijssen RH; Gurney H
    J Clin Oncol; 2009 Jun; 27(16):2578-9. PubMed ID: 19349537
    [No Abstract]   [Full Text] [Related]  

  • 40. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
    Lamas MJ; Duran G; Balboa E; Bernardez B; Candamio S; Vidal Y; Mosquera A; Giraldez JM; Lopez R; Carracedo A; Barros F
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1591-9. PubMed ID: 22535333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.